• Zafgen Inc., of Cambridge, Mass., presented new data from two Phase I studies that showed beloranib, a selective methionine aminopeptidase 2 inhibitor, led to significant weight loss and improvements in cardiometabolic risk markers in severely obese women.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter